<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>: iStockAnalyst.com  Symbols Feed</title>
    <link>http://www.istockanalyst.com</link>
    <description>Custom RSS Feed</description>
    <generator>http://www.iStockAnalyst.com</generator>
    <pubDate>Sun, 08 Nov 2009 22:33:14 GMT</pubDate>
    <language>en</language>
    <ttl>30</ttl>
    <item>
      <title>Biovest Inches Closer To Cancer Vaccine NDA Filing (OTC:BVTI)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3497213</guid>
      <description><![CDATA[As individuals in our respective societies, we all abide by a certain moral standing. However, regardless of your lifestyle, you will adhere to the notion that there is no greater feeling in the world than knowing you are helping fund a company which could potentially save millions of lives, while at the same time fulfilling your needs through growing your pockets as well.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3497213>[More...]</a>]]></description>
      <pubDate>Tue, 22 Sep 2009 17:24:28 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BVTI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3497213</link>
    </item>
    <item>
      <title>Personalized Anti-Cancer Vaccine, BiovaxID®, Targeting B-cell Lymphomas Available in Europe on a Named-Patient Basis</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3317923</guid>
      <description><![CDATA[Biovest International, Inc. (Other OTC:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC:ABPIQ), today announced that BiovaxID&#174;, Biovest’s personalized therapeutic anti-cancer vaccine, is available on a named-patient (compassionate-use) basis in Europe. Following compliance with local regulatory protocols, BiovaxID will be supplied by idis Limited to European healthcare professionals for the treatment of follicular non-Hodgkin’s lymphoma and potentially for other B-cell blood cancers such as chronic lymphocytic leukemia, mantle cell lymphoma and multiple myeloma. Physicians in non-European countries may also contact idis to inquire about the potential availability of BiovaxID, as idis manages named-patient programs in more than 100 countries.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3317923>[More...]</a>]]></description>
      <pubDate>Sun, 28 Jun 2009 11:56:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPIQ</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BVTI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3317923</link>
    </item>
    <item>
      <title>Biovest International Announces Reorganization Plan to Maximize Long-Term Shareholder Value, Fully Pay All Creditors and Continue Operations to Commercialize its Drugs and Technologies</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2783381</guid>
      <description><![CDATA[Biovest International, Inc. (OTCBB:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC:ABPI), today announced that, primarily due to the disruption in the U.S. capital and finance markets which limited access to required funding, the Company has filed a voluntary petition for reorganization. With existing cash flow and the potential for relatively near-term significant business development opportunities for BiovaxID&#174; and AutovaxID™, this action is intended to provide an opportunity for the Company to restore shareholder value and to pay all secured and unsecured creditors. Under protection of the court, Biovest plans to implement a series of initiatives designed to significantly decrease operating expenses and financing costs, and focus cash and resources on its priority programs that will allow the Company to attract key funding/partnering opportunities. Affiliates of the Company, including Hopkins Capital Group, LLC, a major shareholder, have indicated a willingness to provide additional financing to the Company as part of its reorganization plan. A conference call and webcast is scheduled for 4:30 p.m. (EST) this afternoon to further discuss this action.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2783381>[More...]</a>]]></description>
      <pubDate>Mon, 10 Nov 2008 15:30:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BVTI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2783381</link>
    </item>
    <item>
      <title>Biovest and IDIS Announce Agreement to Launch Named-Patient Program for Anti-Cancer Vaccine in Europe</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2747992</guid>
      <description><![CDATA[Biovest International, Inc. (OTCBB:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), today announced that it has executed a distribution agreement with IDIS Limited to exclusively supply BiovaxID&#174; (personalized, anti-idiotype cancer vaccine) under a Named-Patient Program in France, Germany, Italy, Greece, Spain and the United Kingdom. IDIS is a leading European drug distributor, and under terms of this agreement, sales of BiovaxID are expected to commence in the first calendar quarter of 2009, with the anti-cancer vaccine being made available to those patients suffering from various B-cell related blood cancers including: chronic lymphocytic leukemia; mantle cell lymphoma; multiple myeloma; and non-Hodgkin’s lymphoma.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2747992>[More...]</a>]]></description>
      <pubDate>Wed, 29 Oct 2008 13:27:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BVTI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2747992</link>
    </item>
    <item>
      <title>Accentia Biopharmaceuticals to Present at Rodman &amp; Renshaw 10th Annual Healthcare Conference; Company Also Reports On NASDAQ Compliance Plan</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2737290</guid>
      <description><![CDATA[Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today that it will present at the Rodman &amp; Renshaw 10th Annual Healthcare Conference on November 11, 2008 at 10:20 a.m. (EDT) at the New York Palace Hotel in New York City. The Company’s presentation will focus on its BiovaxID&#174; personalized anti-cancer vaccine. Accentia’s majority-owned subsidiary, Biovest International, Inc. (OTCBB:BVTI), recently reported encouraging BiovaxID Phase 3 clinical trial results for the treatment of non-Hodgkin’s lymphoma, and the Company is now progressing with plans to seek approvals in the U.S., Europe and other international countries.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2737290>[More...]</a>]]></description>
      <pubDate>Fri, 24 Oct 2008 21:11:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BVTI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2737290</link>
    </item>
    <item>
      <title>Biovest Announces $1.6M in Federal Funding Appropriated for Groundbreaking Cancer Vaccine &amp; Skin/Bone/Tissue Repair Research</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2729980</guid>
      <description><![CDATA[Biovest International, Inc. (OTCBB:BVTI) today announced that the U.S. Federal Government has approved the appropriation of $1.6 million in biomedical research funds for Fiscal Year 2009 for the Defense Department's Cancer Immunotherapy and Cell Therapy Initiative, which is intended to support research into new applications for the AutovaxID™ instrument, Biovest's fully-automated cell-manufacturing device to cost-effectively and efficiently manufacture difficult-to-produce therapeutic proteins and personalized vaccines, including vaccines targeting cancers.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2729980>[More...]</a>]]></description>
      <pubDate>Wed, 22 Oct 2008 18:57:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BVTI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2729980</link>
    </item>
    <item>
      <title>Biovest Announces BiovaxID(R) Anti-Cancer Vaccine Prolongs Cancer-Free Survival by 44%</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2686607</guid>
      <description><![CDATA[Biovest International, Inc. (OTCBB:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), today provided an update on its personalized, anti-cancer vaccine, BiovaxID&#174;, including reporting clinically and statistically significant data from its randomized controlled pivotal Phase 3 Fast-Tracked clinical trial for the treatment of indolent follicular non-Hodgkin’s lymphoma, an often fatal blood cancer. After a recent meeting with the FDA, the Company closed the clinical trial, unblinded the patients, and analyzed the disease-free survival in both arms through June 30, 2008. The Company has committed to provide the FDA with a detailed clinical report based on this end-of-study data, including statistical analysis, prior to the next meeting in order to discuss a petition to treat all patients in the clinical trial with BiovaxID and to seek Accelerated Approval under subpart E. Originally, the study was intended to follow patients in both arms after unblinding for the purpose of determining overall survival, but based on the trial results, the Company now believes that it would be unethical to withhold BiovaxID from control patients, and that the study, therefore, is closed. Beyond the Company’s U.S. strategy, Biovest disclosed plans regarding preparations to seek approvals in Europe (EU and select non-EU countries), Asia and Australia.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2686607>[More...]</a>]]></description>
      <pubDate>Tue, 07 Oct 2008 15:11:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BVTI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2686607</link>
    </item>
    <item>
      <title>Accentia Reports Fiscal Third Quarter Financial Results</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2515045</guid>
      <description><![CDATA[Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today that the Company has filed its Quarterly Report (Form 10-Q) with the SEC, reporting the results of its operations, including consolidated results with its majority-owned subsidiary, Biovest International, Inc. (OTCBB:BVTI), for its third fiscal quarter ended June 30, 2008.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2515045>[More...]</a>]]></description>
      <pubDate>Thu, 14 Aug 2008 21:36:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BVTI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2515045</link>
    </item>
    <item>
      <title>Biovest Joins in the Formation of the Joint U.S.-Norway Cancer Research Program, a Collaborative Effort with Plans to Present to NCI and the U.S. Military Healthcare System</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2476258</guid>
      <description><![CDATA[Biovest International, Inc. (OTCBB:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), today announced that Biovest has been designated one of the charter members of the Joint U.S.–Norway Cancer Research Program, a collaboration among leading pharmaceutical and biotechnology companies and research organizations with the vision of transforming world-class cancer diagnostics and treatments to improve and extend the lives of cancer patients.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2476258>[More...]</a>]]></description>
      <pubDate>Tue, 05 Aug 2008 13:37:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BVTI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2476258</link>
    </item>
    <item>
      <title>Biovest Announces Conference Call / Webcast to Discuss Phase 3 BiovaxID(R) Anti-Cancer Vaccine Results</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2415332</guid>
      <description><![CDATA[Biovest International, Inc. (OTCBB:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), today announced that the Company will host a conference call and webcast at 4:30 (EDT) this afternoon. Biovest’s Chairman and CEO, Dr. Steven Arikian will discuss the clinically and statistically significant unblinded data recently reported from its randomized controlled pivotal Phase 3 Fast-Tracked clinical trial of BiovaxID&#174; (personalized anti-idiotype vaccine) for the treatment of indolent follicular non-Hodgkin’s lymphoma (NHL), an often fatal blood cancer.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2415332>[More...]</a>]]></description>
      <pubDate>Mon, 21 Jul 2008 12:34:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BVTI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2415332</link>
    </item>
    <item>
      <title>Biovest Reports Results for Patients Treated with Anti-Cancer Vaccine: BiovaxID(R) Demonstrates Clinically and Statistically Significant Improvement of Disease-Free Survival in Non-Hodgkin's Lymphoma in Pivotal Phase 3 Clinical Trial</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2407484</guid>
      <description><![CDATA[Biovest International, Inc. (OTCBB:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), today announced clinically and statistically significant unblinded data from its randomized controlled pivotal Phase 3 Fast-Tracked clinical trial of BiovaxID&#174; (personalized anti-idiotype vaccine) for the treatment of indolent follicular non-Hodgkin’s lymphoma (NHL), an often fatal blood cancer. Originally developed and advanced into human clinical trials by the National Cancer Institute (NCI), BiovaxID is designed to recruit the immune system to recognize and destroy only cancerous B-cells. Based on this study’s highly encouraging clinical evidence reporting on vaccinated patients to date, including efficacy and safety, Biovest intends to move forward with plans to seek accelerated and/or conditional regulatory approvals in the U.S. and European Union, respectively.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2407484>[More...]</a>]]></description>
      <pubDate>Thu, 17 Jul 2008 14:40:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABPI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BVTI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2407484</link>
    </item>
    <item>
      <title>Form  4          OSMAN RONALD E            For: May 22 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3245005</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3245005>[More...]</a>]]></description>
      <pubDate>Tue, 26 May 2009 22:41:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BVTI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3245005</link>
    </item>
    <item>
      <title>Form  4          BIOVEST INTERNATIONAL     For: Oct 06  Filed by: OSMAN RONALD E (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2684323</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2684323>[More...]</a>]]></description>
      <pubDate>Mon, 06 Oct 2008 22:20:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BVTI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2684323</link>
    </item>
    <item>
      <title>Form  4          BIOVEST INTERNATIONAL     For: Sep 26  Filed by: ODONNELL FRANCIS E JR (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2665222</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2665222>[More...]</a>]]></description>
      <pubDate>Tue, 30 Sep 2008 22:25:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BVTI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2665222</link>
    </item>
    <item>
      <title>Form  4          OSMAN RONALD E            For: Sep 18 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2629094</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2629094>[More...]</a>]]></description>
      <pubDate>Thu, 18 Sep 2008 15:21:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BVTI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2629094</link>
    </item>
    <atom:link href="http://www.istockanalyst.com/widget/customsymbolfeed.aspx?symbols=BVTI" rel="self" type="application/rss+xml" />
  </channel>
</rss>